

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/049794 A3

(51) International Patent Classification⁷: **A01K 67/027**,
C07K 16/00, C12N 5/10

(21) International Application Number:
PCT/GB2003/005274

(22) International Filing Date: 3 December 2003 (03.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0228210.1 3 December 2002 (03.12.2002) GB

(71) Applicant (for all designated States except US): **THE
BABRAHAM INSTITUTE** [GB/GB]; Babraham Hall,
Babraham, Cambridge CB2 4AT (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BRÜGGEMANN,
Marianne** [DE/GB]; 2 Station Road, Foxton, Cambridge
CB2 6SA (GB).

(74) Agent: **ROBERTS, Michael, Austin**; Reddie & Grose, 16
Theobalds Road, London WC1X 8PL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
2 December 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

UNOFFICIAL COPY

WO 2004/049794 A3

(54) Title: SINGLE CHAIN ANTIBODIES PRODUCED IN A TRANSGENIC MOUSE

(57) Abstract: The present invention concerns single chain antibodies. The invention includes a transgenic mouse and single chain antibodies produced by such a transgenic mouse. The transgenic mouse may in one aspect be capable of expressing a single chain antibody, such as a heavy chain only antibody, in which expression includes either extracellular display or secretion or both.

INTERNATIONAL SEARCH REPORT

International Application No

T/GB 03/05274

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A01K67/027 C07K16/00 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/085944 A (ERASMUS UNIVERSITEIT ROTTERDAM) 31 October 2002 (2002-10-31) the whole document -----	1-34
X	WO 02/085945 A (ERASMUS UNIVERSITEIT ROTTERDAM) 31 October 2002 (2002-10-31) the whole document -----	1-34
Y	BRUEGGEMANN MARIANNE ET AL: "Strategies for expressing human antibody repertoires in transgenic mice" IMMUNOLOGY TODAY, vol. 17, no. 8, 1996, pages 391-397, XP004034600 ISSN: 0167-5699 the whole document ----- -/--	1-34

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

24 August 2004

Date of mailing of the international search report

06/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

International Application No

:/GB 03/05274

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>RIECHMANN L ET AL: "Single domain antibodies: comparison of camel VH and camelised human VH domains." JOURNAL OF IMMUNOLOGICAL METHODS. 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 25-38, XP004187632 ISSN: 0022-1759 the whole document</p> <p>-----</p>	1-34
Y	<p>KELLERMANN SIRID AIMÉE ET AL: "Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics." CURRENT OPINION IN BIOTECHNOLOGY. DEC 2002, vol. 13, no. 6, December 2002 (2002-12), pages 593-597, XP002293544 ISSN: 0958-1669 the whole document</p> <p>-----</p>	1-34
Y	<p>NGUYEN V K ET AL: "Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire." THE EMBO JOURNAL. 1 MAR 2000, vol. 19, no. 5, 1 March 2000 (2000-03-01), pages 921-930, XP002188947 ISSN: 0261-4189 the whole document</p> <p>-----</p>	1-34
P,X	<p>NGUYEN VIET KHONG ET AL: "Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells." IMMUNOLOGY. MAY 2003, vol. 109, no. 1, May 2003 (2003-05), pages 93-101, XP002293545 ISSN: 0019-2805 the whole document</p> <p>-----</p>	1-34
P,X	<p>WO 03/000737 A (BABRAHAM INSTITUTE) 3 January 2003 (2003-01-03) cited in the application the whole document</p> <p>-----</p>	1-34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

/GB 03/05274

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02085944	A	31-10-2002	BR 0209204 A	06-07-2004
			CA 2445253 A1	31-10-2002
			CA 2445255 A1	31-10-2002
			EP 1414858 A2	06-05-2004
			EP 1381630 A2	21-01-2004
			WO 02085944 A2	31-10-2002
			WO 02085945 A2	31-10-2002
			US 2004142432 A1	22-07-2004
			US 2004137570 A1	15-07-2004
WO 02085945	A	31-10-2002	BR 0209204 A	06-07-2004
			CA 2445253 A1	31-10-2002
			CA 2445255 A1	31-10-2002
			EP 1414858 A2	06-05-2004
			EP 1381630 A2	21-01-2004
			WO 02085944 A2	31-10-2002
			WO 02085945 A2	31-10-2002
			US 2004142432 A1	22-07-2004
			US 2004137570 A1	15-07-2004
WO 03000737	A	03-01-2003	EP 1399559 A2	24-03-2004
			WO 03000737 A2	03-01-2003
			GB 2392672 A	10-03-2004

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/049794 A2

- (51) International Patent Classification⁷: **A01K 67/027**,
C07K 16/00, C12N 5/10
- (21) International Application Number:
PCT/GB2003/005274
- (22) International Filing Date: 3 December 2003 (03.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0228210.1 3 December 2002 (03.12.2002) GB
- (71) Applicant (*for all designated States except US*): **THE
BABRAHAM INSTITUTE** [GB/GB]; Babraham Hall,
Babraham, Cambridge CB2 4AT (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **BRÜGGEMANN**,
Marianne [DE/GB]; 2 Station Road, Foxton, Cambridge
CB2 6SA (GB).
- (74) Agent: **ROBERTS, Michael, Austin**; Reddie & Grose, 16
Theobalds Road, London WC1X 8PL (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 2004/049794 A2

(54) Title: SINGLE CHAIN ANTIBODIES

(57) Abstract: The present invention concerns single chain antibodies. The invention includes a transgenic mouse and single chain antibodies produced by such a transgenic mouse. The transgenic mouse may in one aspect be capable of expressing a single chain antibody, such as a heavy chain only antibody, in which expression includes either extracellular display or secretion or both.

Single Chain Antibodies

The present invention relates to single chain antibodies. In particular, the invention includes a transgenic mouse capable of expressing single chain antibodies and single chain
5 antibodies produced by such a transgenic mouse.

Classical immunoglobulins

Classical antibodies (Abs), and particularly immunoglobulins (Igs), are present in plasma of mammalian species as units of paired heavy (H) and light (L) chains. Each H chain
10 consists of an N-terminal variable (V_H) domain of ~110 amino acids linked to 3 or 4 constant (C) domains of similar size (C_{H1} - C_{H3} or C_{H1} - C_{H4}), while light chains comprise a variable (V_L) domain and a single C domain, C_L . The pairing of H and L chains creates the conventional antigen combining site through the association of V_H and V_L , each domain contributing 3 sets of hypervariable or complementarity determining regions (CDRs) via
15 which contact is made to antigen. Each H-L pair is itself dimerised (H_2L_2), being linked by disulphide bridges connecting the H chains.

There are 5 major H chain isotypes (μ , γ , α , ϵ , δ), which characterise the 5 Ig classes (M, G, A, E and D) and vary in the number of C domains (3 for γ , α , δ or 4 for μ , ϵ). There
20 are two L chain isotypes (κ , λ) which may occur in combination with any H chains. The Ig classes differ in the number of H_2L_2 units they contain; thus IgG, IgD and IgE are single H_2L_2 units, while IgA is a dimer (2 x H_2L_2) and IgM a pentamer (5 x H_2L_2). A detailed review of Ig and antibody structure can be found in Padlan, E.A., Molecular Immunology 1994. 31: 169-217.

25

The route to development of mature classical antibody producing B cells is well established. Early 'pre-B' cells first rearrange H-chain V_HDJ_H segments and proceed to express μ heavy chains on their surface, in association with a surrogate light chain. Subsequently a κ or λ light chain is rearranged and expressed in combination with the H
30 chain. The B cell receptor (BCR) of naïve mature B cells thus includes monomeric IgM (H_2L_2), together with associated signalling domains. After activation and IgM secretion, the process of antibody maturation ensues, during which B cells bearing other Ig isotypes

(IgG, IgA and IgE) are produced by class switching and undergo further selection. Affinity maturation involves a process of hypermutation of the V_H and V_L regions and selection by antigen of binding sites of improved affinity and specificity.

5 Camelid immunoglobulins

In addition to the characteristic classical structures of mammalian Ig's described above, sera of camelids (camels, dromedaries and llamas) contain a major type of Ig composed solely of H-chains (Heavy-chain Abs or HCAs) without L chains (Hamers-Casterman *et al.*, 1993, Nature 363: 446). In such single chain antibodies, the combining site is formed
10 by a single V_H domain, termed V_{HH} . In HCAs, the H chains occur as disulphide bridged dimers. The H chains lack the first constant domain (C_{H1}) (Muyldermans *et al.*, 1994, Protein Engineering 7: 1129). The genes encoding the H-chain contain the $CH1$ exon, which is spliced out during mRNA maturation as a result of a point mutation at the canonical splicing donor site (Nguyen *et al.*, 1999, Mol.Immunol. 36: 515). Single chain
15 HCAs are absent in other mammals except in pathological cases (i.e. heavy chain diseases), where various parts of the V_H domain and the C_{H1} are eliminated due to DNA rearrangements.

The generation of HCAs in the camelid species also relies on the use of specific V_{HH} genes (Nguyen *et al.*, 2001, Adv Immunol. 79: 261), which differ from V_H genes used in
20 the generation of conventional Abs as they carry changes in some of the codons that encode the residues normally contacting the V_L domain.

In camelids, the development of B cells producing HCAs is not well understood. Some
25 observations indicate that the IgM-stage of HCAs is transient and that the conventional IgM pathway might be circumvented in HCAb ontogeny. Possibly a distinct lymphocyte subpopulation might initiate the immune response of the HCAs in camelids. However, the genetic requirements of the BCR and activation in such cells are unknown.

30 Production of single chain antibodies *in vitro*

To date, an *in vitro* molecular approach to construction of single domain combining sites has been used in which V_H / V_L interface mutations are introduced (e.g. G44E, L45R and

W47G) in order to prevent the formation of a domain pair. A repertoire of such single V_H domains was expressed on phage and selected against haptens and proteins, which led successfully to single V_H binding domains of moderate affinity (Riechmann and Muyldermans, 1999, J. Immunol. Methods 231: 25; Davies and Riechmann, 1995, 5 Biotechnology 13: 475). However, there will be several advantages in utilising *in vivo* methods for selection of human HCABs, particularly in the use of transgenic mice.

Human immunoglobulins in transgenic mice

Because of their clinical therapeutic advantages for treatment of diseases including 10 cancers and infections, several procedures have been explored for production of human antibodies, avoiding immunisation of humans. They include molecular techniques of 'humanisation', in which CDRs from mouse antibodies replace the human CDRs in human V region frameworks, selection of binders from genetic libraries of human antibody combining sites by phage display *in vitro*, and expression of human Ig genes in 15 transgenic mice. In the last of these, elements of the human H and L genetic loci, including V_Hs, Ds, J_Hs and V_Ls and J_L segments with C region genes all in germline configuration, are cloned into yeast artificial chromosomes and introduced into mouse embryonic stem cells. In the transgenic animals thus obtained, B cells rearrange the human V genes in normal fashion (i.e. V_HDJ_H and V_LJ_L) and express fully human Ig's, 20 responding to immunisation by production of fully human antibodies. Optimally, the expression of endogenous mouse Ig is suppressed by knockout of the mouse H and L chain loci. A number of different knockout strategies have been employed, such as silencing of H chain expression by deletion of the μ chain membrane domain (Kitamura *et al.*, 1991, Nature 350: 423) and inactivation of the L chain locus by deletion of J_L 25 segments. After immunisation of such multifeature transgenic knockout mice, human monoclonal antibodies can be obtained by the hybridoma method, and such mice are now used for the production of therapeutic human antibodies (for review see Brüggenmann and Taussig, 1997, Curr Opin Biotechnol 8: 455).

30 Present invention

Significant advantages may be achieved by the use of single domain or single chain antibodies rather than conventional antibodies, for example for human therapeutic or

diagnostic reagents, such advantages deriving from their unique reactivity against active sites of target molecules and rapid tissue penetration. However, it is evident that appropriate new methods are required for their production. The *in vitro* display library approach requires considerable time-consuming and labour-intensive genetic
5 manipulations and know-how to produce desired binders and in the literature has resulted in selection of human single chain antibodies of relatively low affinity. However, no means currently exists for the production of single chain antibodies in mammals other than those naturally occurring in camelids.

10 According to the present invention, there is provided a transgenic mouse capable of expressing a single chain antibody, in which expression includes either extracellular display or secretion or both.

Transgenic mice of the invention have the capacity to express, on their B cells and/or in
15 plasma, single chain antibodies. An advantage in the use of animals for the production of classical antibodies lies in the natural process of selection and affinity maturation which occurs in B cells of the immunised animal *in vivo*, resulting in a potentially quicker and easier derivation of desired antibodies.

20 As noted above, the formation of HCABs in camelids appears to require both the involvement of a V_HH germline gene in which the interface residues are modified and the availability of the HCAB-specific C_H (C_γ) gene. However, the details of transcript processing and the extent of the C_H1 removal from the V_HHDJ - C_γ primary transcript remains presently obscure. Furthermore, because HCABs were observed exclusively in
25 camelids and not in other mammalian species it was thought that HCAB production may involve camelid-specific accompanying specific factors to process, assemble and express HCAB genes into functional antigen-binding entities. For these reasons, the ability to utilise a noncamelid species to produce *bona fide* HCABs, as demonstrated here for the first time, is an unexpected result.

30

Herein the term 'single chain antibody' designates in a first embodiment an Ig H chain, unpartnered by L chain. The H chain may carry a V region linked to C_H domains and

capable of binding to antigen ligand via a single V domain. Alternatively, a single chain antibody may designate a combination of the domains of an Ig H and Ig L chain to form a chimeric single chain antibody. A 'single domain antibody', also covered by the present invention, is defined as an unpaired V region capable of binding to an antigen ligand.

5

The single chain antibody of the transgenic mouse may thus be a heavy chain antibody. The single chain antibody may in a further embodiment comprise a heavy chain domain linked to a light chain domain.

10 The transgenic mouse may carry immunoglobulin heavy and/or chain locus genes of a heterologous species for single chain antibody expression. The heterologous heavy and/or light chain locus genes may include V_L and/or V_H , and/or D and/or J_H and/or C genes. A heterologous heavy chain locus gene may be modified (for example by mutation and/or deletion) to allow expression and/or antigen binding of the single chain antibody. For
15 example, a C region exon (for example, the C_H1 exon) of the heterologous heavy chain locus gene may be modified. Alternatively or additionally, the V_H and/or complementary determining regions (CDRs, i.e. hydrophobic residues located in the conventional V_H/V_L interface and which take part in domain-domain interaction) may be modified.

20 We have demonstrated previously (see International Patent Application No. PCT/GB02/02867 published as WO03/000737) that deletion of the L chain loci by knockout does not lead to production of single chain antibodies capable of being expressed, indicating that further modification may be required.

25 In one embodiment, the heterologous heavy and/or light chain locus genes in the transgenic mouse are not rearranged and comprise a repertoire of V_H , D and J_H segments, or V_L and J_L segments, and a constant region gene.

In a further aspect of the invention, the transgenic mouse comprises a repertoire of genes
30 encoding rearranged or germline variable V_H or V_L domains of a heterologous species, modified for single chain antibody expression and optionally antigen binding by modification of variable-region framework and/or CDR residues and/or constant-region

genes.

In the transgenic mouse of the invention, any or all of the endogenous mouse heavy chain genes and/or light chain genes may be modified, functionally silenced and/or deleted. This
5 can, for example, allow for expression of specific heterologous antibodies only.

The single chain antibody may be in monomeric or multimeric (for example, dimeric) configuration.

10 The transgenic mouse may express a repertoire of single chain antibodies. The heterologous heavy and/or light chain locus genes or the repertoire of genes may undergo rearrangement and expression in mouse B cells. Immunoglobulin gene segments can be rearranged in B cells *in vivo* and the mouse may thus respond to immunisation by production of a variety of single chain Abs, for example, of the heterologous species. For
15 example, different V_H genes may be rearranged with different D and J segments.

Mixed loci may be used for the creation of single (e.g. heavy) chain antibody repertoires. It may be advantageous to mix genes or segments of intervening sequences from different species to improve single chain antibody expression.

20

The heterologous species may be mammalian, for example a noncamelid such as a human.

For clinical applications in man, single domain combining sites (as in HCABs), currently only known naturally in camelids and sharks, would advantageously be of human origin
25 and potentially combined with human constant regions in order to avoid problems of immunogenicity.

In another aspect of the invention there is provided a method for the production of a transgenic mouse capable of expressing a single chain antibody having a heavy chain or a
30 heavy chain linked to a light chain, comprising the steps of inserting immunoglobulin heavy or light chain locus genes of a heterologous species into the mouse, allowing expression of the genes to form the single chain antibody which is expressed either by

extracellular display or by secretion or both.

In a further aspect of the invention there is provided a single chain antibody produced by the transgenic mouse as defined above. The single chain antibody may be in the form of a monomer or multimers in which identical chains are associated. Alternatively, the single chain antibody may be in dimeric or multimeric form such that variable domains of the antibody bind antigen independently.

Also provided according to the invention is a monoclonal or polyclonal heavy chain only antibody, or a heavy-light chain chimeric antibody, which has a structure including a single domain antigen-combining V_H or V_L region and which is made upon immunisation of a mouse as defined above.

Yet further provided is a method for producing a single chain antibody of the invention, comprising the step of immunising the mouse as defined above with an antigen to elicit an immune response, the immune response comprising antigen-specific antibody production.

Another aspect of the invention is an antibody display library derived from the transgenic mouse as defined above, in which the display library comprises immunoglobulin heavy and/or light chain genes which are transcribed and translated *in vitro* to encode a population of single chain antibodies. The library may comprise lymphocyte DNA isolated from a mouse as defined above.

Also provided according to the invention is a method for the production of the display library as defined above, comprising the step of introducing the immunoglobulin heavy and/or light chain genes into a bacterial, yeast, phage or ribosome display system.

A further aspect of the invention is an isolated non-camelid immunoglobulin locus comprising heavy chain genes modified to encode a single chain antibody capable of being expressed *in vivo*. The locus may further comprise light chain genes. The heavy and light chain genes may comprise variable genes which are modified at their V_H/V_L interface.

The invention also provides a hybridoma obtainable from a transgenic mouse as defined herein by fusion of a splenocyte from the transgenic mouse with a B-cell tumour line cell (for example an NSO myeloma cell), and subsequent selection of single clones. Also
5 provided is a single chain antibody, preferably human, obtainable from this hybridoma.

As well as generation of hybridomas, human genes encoding single chain antibodies may be recovered from the immune B cells of transgenic mice by PCR for further genetic manipulation.

10

Whereas the antigen-combining site of a conventional antibody is provided by the association of V_H and V_L domains, that of single chain antibodies may include a V_{HH} domain only and consequently be much smaller in size than that of classical antibodies. This provides single chain antibodies certain advantageous properties, such as the ability
15 to recognise smaller antigens, for example the binding site clefts on the surfaces of enzymes where active sites are located or canyons on the surfaces of viruses, both regions which may be inaccessible to the combining sites of conventional Abs. In camelids, this may be assisted by the CDR3 region of the HCAB, which may be particularly long and include a disulphide bridge. In addition to their special specificity properties, single
20 domain combining sites may have advantages as therapeutic and diagnostic agents in their easier penetration into target tissues such as tumours and more rapid clearance from the human body. A further aspect of the invention therefore covers use of single chain antibodies according to the invention as a therapeutic and/or diagnostic agent. Single chain antibodies of the invention may be used in the manufacture of a medicament for the
25 treatment of a disease, for example cancer.

In another aspect of the invention there is provided a method for producing a repertoire of single chain antibodies in a mouse. The method may use the mouse as defined above. The method may encompass the method for producing the antibody as defined above. The
30 repertoire may comprise single chain antibodies of the invention as defined above. Also provided according to the invention is a repertoire of single chain antibodies produced by the method.

Various embodiments of the invention will be described below with reference to the accompanying figures, of which:

5 Figure 1: depicts constructs of V_HH- γ 2a with ("V_HH-C γ 2aTM"; top figure) or without ("V_HH-C γ 2a"; bottom figure) transmembrane (TM) exons;

Figure 2: shows ELISA results detecting hen egg-white lysosyme (HEL)-specific dromedary Ig produced by transfected NSO mouse myeloma cells carrying the V_HH-C γ 2aTM, V_HH-C γ 2a or parental pSV2 vector transcripts. OD = optical density (values at
10 405 nm);

Figure 3: shows an SDS-PAGE of camel HCAs from transfected NSO mouse myeloma cells carrying the V_HH-C γ 2aTM, V_HH-C γ 2a or parental pSV2 vector transcripts, stained with Coomassie brilliant blue (panels A and B) or revealed by Western blotting
15 (panels C and D);

Figure 4: illustrates the predicted structure of two mRNA products, with (panel A, top) and without (panel A, bottom) C_H1, that could be obtained from a rearranged camel
20 Ig H-gene. Panels B to D show PCR identification of transcription products from transfected NSO mouse myeloma cells carrying the V_HH-C γ 2aTM, V_HH-C γ 2a or parental pSV2 vector transcripts;

Figure 5: shows flow cytometry of NSO mouse myeloma cells transfected with V_HH-C γ 2aTM (A, D), V_HH-C γ 2a (B) or parental pSV2 vector only (C). Panel (D) shows cells stained with biotinylated rabbit anti-dromedary Ig and with FITC labeled streptavidine prior to (shaded histogram) or after (open profile) incubation with phosphatidyl-inositol-specific phospholipase C (PI-PLC) to reveal BCR configuration;

30 Figure 6: shows PCR analysis of transgenic mice containing the camel V_HH-C γ 2a transgene;

Figure 7: shows ELISA results detecting camel single chain antibodies detection in transgenic mice containing the V_HH-C γ 2a transgene. The left panel shows HEL-specific camel Ig in serum from transgenic mice while the right panel shows HEL-specific camel Ig in serum from normal mouse;

5

Figure 8: shows FACS analysis of B cells in normal mice (left), transgenic mice carrying the V_HH-C γ 2a construct in a μ MT^{-/-} heavy chain knockout background (centre), and control μ MT^{-/-} mice (right);

10 Figure 9: shows flow cytometry analysis of B cells from bone marrow (left three rows) and spleen (right three rows) from normal F1 mice, μ MT mice and two separately generated camel heavy chain mice bred to homozygosity with μ MT animals, viz. camIgH(1) μ MT and camIgH(2) μ MT;

15 Figure 10: depicts a IgH YAC construct (prior art) from Nicholson, I.C. *et al.* (1999) J. Immunol. 163: 6898-6906; and

Figure 11: depicts a IgH γ^A YAC construct which is modified from the IgH YAC construct of Figure 10 by truncation and removal of the C gene.

20

Experimental

In the examples provided below, we have demonstrated herein the expression of a rearranged camelid single chain antibody in transfected mouse myeloma cells (Example 1). The expression of the camel V_HH- γ 2a gene followed by the proper mRNA processing, translation, folding and secretion of functional HCAb by the mouse myeloma cell line proves that the HCAb features are all imprinted into the germline genes, and that additional camel-specific infrastructures are not essential or can be by-passed by the mouse transcription, translation and secretion mechanisms. Moreover, in Example 2 we demonstrate the presence of camelid HCAb in the plasma of transgenic mice carrying the HCAb V_HH- γ 2a gene. In Examples 3 and 4, we demonstrate and analyse the rescue of B cell development in heavy chain knockout mice by the HCAb transgene. Examples 5 to 7 relate to expression of appropriately modified human V_H or V_L genes as single chain antibodies in transgenic mice.

15

Example 1: A camel heavy-chain antibody secreted and displayed by mouse myeloma cells

This work is focused on the first step in construction of transgenic mice expressing HCAb, i.e. whether mouse B cells can express heterologous HCAs derived from Camelidae species. Rearranged camel H-genes encoding HCAb (V_HH- γ 2a) with and without the transmembrane ("TM") bound region were constructed and their expression, processing and assembly in mouse NSO myeloma cells were examined. A camel H chain gene encoding a HCAb IgG2a isotype with specificity for hen egg-white lysozyme (HEL) was reconstituted and electroporated into the NSO mouse myeloma cell line, which has no endogenous Ig H or L chain expression. The C_H1 domain exon was present in the recombinant gene, but was removed efficiently from the heterologous H-chain transcripts within the cell. HEL-specific HCAs were secreted as disulfide linked homodimers with MW (2 x 50 kDa) as found for the HCAs naturally occurring in camel serum. Antigen-binding HCAs were displayed on the surface of the mouse cell as GPI-linked B cell receptors (BCR) when the transmembrane exons were present in the recombinant gene. The possibility of obtaining expression of a BCR in a HCAb format suggests that

30

maturation of HCABs could occur in complete absence of L-chains. The findings demonstrate the feasibility of the expression and maturation of HCABs in mouse B cells.

Construction of a dromedary V_HH-γ2a H-chain gene

- 5 The rearranged H-chain genes, constructed from V_HH and Cγ2a genes used in the dromedary to form HCABs, are shown in Figure 1. The two constructs differ in the presence or absence of the transmembrane TM region and represent a camel rearranged gene in a genomic configuration with appropriate 5' and 3' regions to allow expression.
- 10 DNA manipulations were carried out using standard PCR and DNA subcloning techniques (Sambrook J, *et al.* 1989, In: A laboratory manual. Cold Spring Harbor Laboratory Press, especially pp. 2.64-2.68; 6.3-6.15; 6.16-6.22; 9.14-9.23). In intermediate cloning steps, recombinant plasmids (pBluescript) were propagated in *E.coli* DH5α cells, and DNA was prepared using a Qiagen-mini® prep kit (Qiagen, Westburg, Leusden, The Netherlands).
- 15 The cloning strategy was as follows: the Ig promoter region derived from the germline V_HH clone cvh11 (Nguyen *et al.*, 2000, EMBO J. 19: 921-930) was spliced by overlap PCR with the FR1 region of the V_HHDJ gene encoding the lysozyme-specific cAb-Lys3 (Desmyter A. *et al.*, 1996, Nat. Struct. Biol. 3: 803-811). The region from J_H5 to the C_H1 exon of the Cγ2a gene rearranged to a V_HHDJ part with unknown specificity (clone rg122
- 20 obtained by PCR; see Fig. 1) was added as a BstEII-EcoRI fragment, and the remaining exons of the Cγ2a gene in germline configuration (clone ch51666; Nguyen *et al.*, 1999, Mol. Immunol. 36: 515, including both transmembrane (TM) exons, were added on an EcoRI-SalI fragment (Fig. 1). The 11.7 kb H-chain construct, including the TM segments on a NotI-SalI fragment, and the 7.4 kb H-chain construct, without the TM region on a
- 25 NotI-KpnI fragment, were subcloned into pSV2-Neo#459 (LMB, Cambridge, UK) at pre-introduced NotI-SalI and NotI-KpnI cloning sites, respectively. The constructs were named V_HH-γ2aTM and V_HH-γ2a (see Fig. 1).

- 30 The cAb-Lys3 is a V_HH coding for a HEL-specific single domain antibody fragment. The arrow at the left in Fig. 1 denotes the Ig promoter starting with the conserved Ig octamer sequence. The other gene components are boxed: the rearranged V_HHDJ region encoding the cAb-Lys3 sequence, the J_H6 (not used in the D-J recombination), the enhancer (E),

matrix attachment region (MAR) and switch region and the different exons (C for constant domains and M for transmembrane regions) of the dromedary $\text{C}\gamma 2\text{a}$ are indicated. The position of the NotI, BstEII, EcoRI, SalI and KpnI restriction enzyme sites used during cloning and screening are indicated as well as the position of the stopcodons (\$). The star
5 denotes the non-canonical splicing site at the 3' end of the $\text{C}_\text{H}1$ of the camel $\text{C}\gamma 2\text{a}$ gene. The $\text{V}_\text{H}\text{H}-\text{C}\gamma 2\text{aTM}$ construct (Fig. 1, top) of 11.7 kb is the part comprised between the unique NotI and SalI sites, and the $\text{V}_\text{H}\text{H}-\text{C}\gamma 2\text{a}$ construct (Fig. 1, bottom) of 7.4 kb, comprised between the NotI and KpnI sites, lacks the membrane bound exons. (The space between E-MAR and switch region is not to scale.)

10

Transfected NSO cells secrete HEL-specific Abs

The $\text{V}_\text{H}\text{H}-\gamma 2\text{aTM}$ or the $\text{V}_\text{H}\text{H}-\gamma 2\text{a}$ gene constructs or the parental pSV2-Neo cloning vector used as control were electroporated separately into NSO myeloma cells (Desmyter A. *et al.*, 1996, *supra*) by 2 pulses using a BIORAD Gene Pulser set at 230 V and 500 μF . The
15 transfected NSO cells were maintained at 37°C and 5% CO_2 in RPMI 1640 medium containing 10% FCS. After 24 hrs of growth, G418 (Invitrogen, Paisley, UK) was added to a final concentration of 400 $\mu\text{g}/\text{ml}$. At least 5 antibiotic resistant clones were chosen for each construct and grown to a density of $2-3 \times 10^5$ cells/ml for further studies.

20 HEL (10 $\mu\text{g}/\text{ml}$ in PBS) was coated overnight at 4°C onto 96-well-plates (Nunc-MaxisorbTM, Life Technologies, Invitrogen, Merelbeke, Belgium). Residual protein binding sites were blocked with PBS-1% casein for 2 hrs at room temperature. Serial five-fold dilutions (100 μl) of cell-free supernatants from different clones of the transfected NSO cells were added to the wells and incubated at room temperature for 1 hr. The
25 retention of recombinant HEL binding Abs (anti-HEL-IgG2a) was detected with rabbit anti-camel IgG (1/1000 anti-dromedary rabbit serum R17, provided by T. Serrao, VUB, Brussels) and alkaline phosphatase-conjugated goat IgG directed against rabbit IgG (Sigma-Aldrich, Gillingham, UK) and p-Nitrophenyl Phosphate (pNPP) as substrate. Substrate hydrolysis was blocked after 15 min reaction with 1/10 volume of 0.5M EDTA
30 and the plates were read at OD 405 nm in a microtiter plate reader (Elx808, Bio-Tek Instruments, Winooski, Vermont).

Figure 2 shows the HEL specific recombinant molecules of three individual clones (clones 1, 2 and 3) identified using the above ELISA. The positive control (Ctrl+) contains camel anti HEL antiserum diluted 1/5000. Clones 1 and 3 for constructs V_HH- γ 2aTM and V_HH- γ 2a respectively gave ELISA signals similar to those of the positive control and were inhibited by free HEL (not shown). These results demonstrate that murine NSO cells transfected with the V_HH- γ 2aTM or V_HH- γ 2a constructs can express a camel H-chain gene and secrete antigen-specific products as a result of correct splicing, translation and intracellular folding.

10 *Dromedary HCABs produced in mouse cells*

The camel HCABs secreted by the NSO cells were characterized by SDS-PAGE and Western blotting, after absorption and elution from HEL-coupled Sepharose, or visualized by Western blot using rabbit anti-camel IgG (Figure 3). Recombinant HCAB was enriched on immuno-adsorbent obtained by coupling HEL to CNBr-activated Sepharose (Amersham Pharmacia, Little Chalfont, UK) (3 mg HEL per ml resin) in 0.5 M NaCl and 0.1 M NaHCO₃ pH 8.3 following the instructions provided by the manufacturer. HEL-coupled Sepharose (50 μ l wet gel) was incubated with 0.5 ml culture supernatant of the different NSO transfectants for 1 hr at room temperature and washed repeatedly with PBS. The captured proteins were solubilized by adding 100 μ l SDS-sample buffer, boiled and 4 μ l applied to a 10% polyacrylamide gel. SDS-PAGE was carried out under reducing (0.5% DTT in the loading buffer) and non-reducing conditions. Fractionated IgG1 Abs and IgG2 HCABs isolated from dromedary serum were applied in adjacent lanes as references. To visualize the proteins after electrophoresis, gels were stained using Coomassie Brilliant Blue. For Western blot analysis, proteins separated on SDS-PAGE were transferred onto nitrocellulose membranes (Amersham Pharmacia), using a Mini Trans-Blot Cell (BioRad, Nazareth EKE, Belgium) and following standard protocols (Galfre *et al.*, 1982, Immunology 45: 125-128). The recombinant IgG2a enriched by adsorption was detected with rabbit anti-dromedary serum as first Ab, alkaline phosphatase-conjugated goat anti-rabbit IgG as second Ab (the same reagents as in ELISA), and 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium (BCIP/NBT, Sigma-Aldrich) as substrate.

Culture supernatant was applied from NSO cells transfected with V_HH-C γ 2a-TM (Fig. 3, lanes 1), V_HH- C γ 2a (Fig. 3, lanes 2) and parental pSV2 vector only (Fig. 3, lanes 3). As controls, the isotypes fractionated from dromedary serum were loaded in adjacent lanes: IgG1, the conventional H-L containing Abs (Fig. 3, lanes 5) and the HCAb IgG2 (Fig. 3, lanes 6). All proteins were separated under non-reducing (Fig. 3, panels A and C) or under reducing conditions (Fig. 3, panel B and D). The molecular weight marker is a prestained protein ladder, and the sizes (in kDa) are given along the bands. The amount of material applied in the Coomassie blue stained gels was ten times higher than in gels revealed by Western blotting.

10

Western blotting revealed a specific protein in the culture supernatants of the NSO transfectants of the V_HH- γ 2aTM or V_HH- γ 2a constructs, the molecular weight of which was below the 114 kDa protein marker under non-reducing conditions, and shifted to ~50 kDa under reducing conditions (Fig. 3, lanes 1 and 2). This result is consistent with disulphide-linked H chain homodimers secreted by the NSO cells as found for HCAbs produced by camelids (Fig. 3, lanes 6). The finding (Fig. 3B, D) that the molecular weight of the H chains of the recombinant HCAb (lanes 1 & 2) is lower than that of conventional camel H chains (lane 5) is consistent with the expected absence of the C_H1 domain. We conclude that the HEL-specific single chain camel Abs are secreted by the transfected NSO cells in a homogeneous form with the MW expected of the IgG2a single chain Abs occurring naturally in camel. The secretion level of the most productive clone (10mg/ml) was similar to the levels obtained from endogenous Abs expressed in myeloma cells.

25 *H chain splicing in transgenic NSO cells*

In order to confirm that the mouse cells do in fact remove the C_H1 exon from the V_HH- γ 2a(TM) transcript, RT-PCR analysis was performed, with primers to amplify the sequence from the V_HH FR1 to the hinge region (Figure 4).

30 The QuickPrep micro mRNA purification kit (Amersham Pharmacia) was used for the preparation of mRNA from 10⁷ transfected NSO cells and first strand cDNA was synthesized using the 'Ready-to-Go' kit (Amersham Pharmacia). PCR conditions using

0.5 µl cDNA were: 30 cycles of 45 s at 94°C, 30 s at 52°C and 45 s at 72°C. Three combinations of specific oligonucleotides allowed the analysis of the C_H1 splicing junctions: (1) V3FR1B (5' GAGGTGCAGCTGGTGGCGTCTGGAGGAGG 3'; SEQ ID NO: 1), derived from the sequence of the V_HH/V_H-FR1 region and G2AHIF (5' GGGACACGTGCATTCTGGTTCA 3'; SEQ ID NO: 2), a sequence annealing at the long hinge region of dromedary Cγ2a; (2) V3FR1B and CH1290F (5' CTCTTGTCGACCTTGGTGCTGCTG 3'; SEQ ID NO: 3), representing a conserved sequence of the first constant exon of all camelid Cγ genes; and (3) CH1242B (5' GCATCTAGACCGMAAGACCTTCAYCT 3'; SEQ ID NO: 4), a consensus sequence of the first constant exon of all camelid Cγ, and the long hinge-specific G2AHIF primer. A lack of the C_H1 exon sequence from the mRNA will result in a ~0.5 kb PCR fragment employing oligonucleotides (1) whilst no amplification products are expected in PCR reactions using oligonucleotide combinations (2) and (3).

Fig. 4(A) illustrates the predicted structure of two mRNA products, with and without C_H1, that could possibly be obtained from the rearranged camel Ig H-gene. The theoretically possible PCR amplification fragments of these mRNAs are indicated with the expected sizes in kb.

RT-PCR product amplified from the V_HH-FR1 to the hinge (Fig. 4, panel B), from the V_HH-FR1 to the C_H1 (Fig. 4, panel C), and from the 5' C_HH1 end to the 3' hinge (h) end (Fig. 4, panel D), in which mRNA templates are derived from either, the NSO cells harbouring the dromedary V_HH-Cγ2a-TM gene (lanes 1), V_HH- Cγ2a (lanes 2), parental pSV2 vector (lanes 3) are shown. The fourth lane shows the 123 bp size ladder (position of 123 bp monomer is indicated in panel B). In lane 5, the PCR products of the cloned dromedary Ig-γ1 cDNA possessing the C_H1 exon. This gives the expected C_H1 containing fragments of 695 bp (0.7 kb), 646 bp (0.65 kb) and 334 bp (0.3 kb) with primers used to perform experiments shown in B, C and D, respectively.

With oligonucleotides V3FR1B and G2AHIF, the mRNA from the transfected NSO cells as template resulted in a single fragment of 0.5 kb, identifying the transgenic mRNA product without C_H1 (Fig. 4B, lanes 1 and 2). No band was discerned with a size of 0.8 kb

that would result from the mRNA in which the C_H1 exon sequences would have been retained. The absence of the C_H1 exon in the V_HH-γ2a spliced products was further shown by RT-PCR using C_H1-specific oligonucleotides which failed to amplify any products (Fig. 4C & 4D, lanes 1 and 2).

5

Display of HEL-specific HCAs on the mouse cell surface

Flow cytometry of the NSO transfectants is shown in Figure 5. HEL and affinity-purified rabbit anti-camel IgG were biotinylated using biotin-X-sulfo-NHS (Calbiochem, Nottingham, UK). Clones from the NSO transfectants (10⁶ cells) were resuspended in 200
10 μl RPMI medium and incubated with 1 mg biotinylated HEL at 4°C for 45 min. Unbound antigen was removed by two washings with PBS containing 0.002% TritonX-100 and 0.01% sodium azide, and FITC-labeled streptavidin (PharMingen, San Diego, CA) was added to detect cells that captured HEL. After 30 min incubation the cells were washed and resuspended in 2 ml PBS. The cells were analyzed with a FACSvantage flow
15 cytometer (Becton Dickinson, Mountain View, CA). To analyze the H-chain anchorage in the membrane, the cells were incubated with 10U/ml phosphatidyl-inositol-specific phospholipase C (PI-PLC) (ICN, Cedarwood, Basingstoke, UK) prior to staining with biotinylated rabbit anti-camel IgG and FITC-labeled streptavidin. Untreated cells were used as control.

20

Figure 5 shows cells transfected with V_HH-Cγ2aTM (A, D), V_HH-Cγ2a (B) and vector only (C) that were incubated with biotinylated HEL and stained with FITC-labeled streptavidin. The background signal obtained when the biotinylated HEL was omitted is superimposed (shaded histograms). In panel D, cells transfected with V_HH-Cγ2aTM were
25 stained with biotinylated rabbit anti-dromedary Ig and with FITC labeled streptavidine prior to (shaded histogram) or after (open profile) incubation with PI-PLC. Each histogram shows the analysis of approximately 10⁴ cells.

Labelling of the NSO transfectants carrying the V_HH-Cγ2aTM construct, with either
30 biotinylated HEL or biotinylated rabbit anti-camel IgG, followed by FITC-labeled streptavidin, led to the identification of surface Ig⁺ cells (Fig. 5A and 5D). The surface signal intensity was surprising and implied that heterologous HCAs are efficiently

transported and anchored in the mouse cell membrane. To identify the cell surface anchoring type of the HCABs, transfectants were incubated with phosphatidyl-inositol-specific phospholipase C (PI-PLC) which specifically releases GPI-linked proteins from the cell surface. The results (Fig. 5D) show a net reduction in fluorescence intensity upon
5 PI-PLC treatment of the cells, reflecting the removal of GPI-linked surface Ig. Therefore, the data demonstrate that camel HCABs devoid of L-chain can be transported to and expressed on the cell surface of NSO mouse cells as a GPI-linked protein.

Summary

10 The results of Example 1 confirm removal of the CH1 domain by mouse B cells, which allows expression of camel HCAB. In the presence of a transmembrane domain, the HCABs are also found on the B cell surface. This has major implications for the formation of antibody repertoires because the B cell receptor is essential to allow cell survival and progression of B-cell development. The successful expression of HCABs by mouse cells
15 suggests that developmental regulation of HCABs in a transgenic mouse and in vivo HCAB expression and maturation is feasible.

Example 2: Antigen-specific single chain camel antibodies in transgenic mouse

20 Mice, and all other healthy non-camelidae mammals studied, do not express single chain antibodies and there are no reports that B-cell development can progress without expression of Ig H and L (light) association on the cell surface. In order to determine whether camel-type H chains could be expressed in a transgenic mouse, retaining their specificity and the effect on B-cell development and B-cell receptor (BCR) configuration,
25 transgenic mice were constructed.

The V_HH -C γ 2a TM construct (see Example 1) was introduced into the germline of F1 CBA x C57BL/6 mice by conventional DNA injection into fertilised mouse eggs (Hogan, B. *et al.* 1994, Production of transgenic mice, In: Manipulating the mouse embryo,
30 a laboratory manual, Cold Spring Harbour Laboratory Press, pp 217-251).

Following reimplantation into pseudopregnant F1 females, several mice were obtained

carrying the camel heavy chain gene in multiple copies in their genome. Integration of the camel H chain gene was verified by PCR using mouse tail DNA prepared according to Matisse *et al.* (2000, Gene Targeting: A practical approach, Joyner, Ed., Oxford University Press, p.122). PCR was performed using CamIgH Primer 1 (5'-
5 GCATCTAGACCGGAAAGACCTTCATCT-3'; SEQ ID NO: 5) and CamIgH Primer 2 (5'-GGGACACGTGCATTCTGGTTCA-3'; SEQ ID NO: 2). PCR conditions were: 94°C for 3 min and then 94°C, 55 s; 52°C, 40 s and 72°C, 55 s for 30 cycles with a final extension of 10 min. The expected product size is 486 bp.

10 Figure 6 shows the PCR results for the following lanes: 1) control no DNA; 2) normal mouse DNA; and 3-6) transgenic camel antibody mice. A λ -based ladder flanks the PCR lanes. In lanes 3-6 containing amplification products from transgenic camel antibody mice, but not the control and normal mouse DNA lanes, a band of about 486 bp was generated (compare with strong 600 bp band of λ -based ladder). The results in Figure 6
15 confirm that camel-type H chains can be expressed in transgenic mice.

In the camel this V_H chain is expressed as a single chain antibody in dimeric H₂ form with specificity for HEL. We could not determine how or whether the antibody produced in the transgenic mice are surface-expressed because of the low affinity of the anti-HEL antigen
20 in the construct. Analysis of expression using anti-camel antibodies was not feasible because of their reactivity with other mouse antigens.

In order to confirm expression of the single chain antibody in the transgenic mouse, ELISA assays for camel Ig HEL binding activity were carried out using serum obtained
25 from the tail vein blood from each of the 3 separately derived transgenic founder mice. HEL-specific single chain antibodies in serum of transgenic mice carrying the V_HH-C γ 2a transgene were detected using 96-well Dynatech microtiter plates coated with 50 μ l of 10 μ g/ml hen egg lysozyme and blocked with 3% BSA overnight. Serum (50 μ l) at various dilutions (1:10, 1:100, 1:1000 or 1:10000) was added and incubated for 2 hours at room
30 temperature. Normal mouse serum was used as control. Binding was detected with biotinylated antibodies against camel H chain or mouse H and L chain and developed with streptavidin horse radish peroxidase and visualised with o-phenylenediamine substrate.

Results shown in Figure 7 demonstrate the presence of camel HCAb against HEL in transgenic, but not normal mouse control, serum, confirming the expression of the HCAb transgene. A detailed serum analysis showed that camel Ig levels were similar to normal
5 mouse Ig levels and that the camel H chain was not associated with mouse H or L chain.

These experiments demonstrate that it is possible to create transgenic mice producing single chain antibodies and that mouse B cells are therefore able to process the genetic information for such antibodies effectively.

10

Example 3: Rescue of B cell development by introduction of single heavy chain antibody gene in transgenic mice

In order to show that the camel HCAb transgenic antibodies can be expressed
15 independently of B-cells producing mouse antibodies, the transgenic camel HCAb mice of Example 2 above carrying the V_HH-C γ 2a construct were crossed with mice in which the endogenous H chain locus was silenced by gene targeting (μ MT mice, Kitamura *et al.*, 1991, *supra*).

20 Flow cytometry analysis (see Example 1 for general method) was carried out using spleen cells. Mice were sacrificed, spleens removed and cell suspensions prepared. Cells were stained using anti-mouse B220 antibodies (01125A, 01129A, PharMingen, San Diego, CA) and for FACS analysis lymphocytes were gated according to their expected size.

25 Results are shown in Figure 8 for normal mice (left), transgenic mice carrying the V_HH-C γ 2a construct in the μ MT^{-/-} heavy chain knockout background (centre), and control μ MT^{-/-} mice (right). The percentage of B cells in each spleen preparation are indicated. FACS analysis revealed that B cells were rescued in the transgenic mice in the μ MT^{-/-} background, with good recovery of B-cell development. Indeed from the results it is clear
30 that a substantial number of B-cells leave the bone marrow and settle in the spleen. Since the μ MT^{-/-} mouse is normally devoid of B cells (see controls in Figure 8), it is clear that the camel HCAb transgene rescues B cell development.

We conclude from these experiments that a single chain antibody of camel origin is successfully processed and expressed in mouse B cells, both when transfected in cell culture and when incorporated into the mouse germline as a transgene.

5

Example 4: B-cell development in mice expressing camel heavy chain antibodies

Transgenic mice carrying the camel heavy chain gene (were bred to homozygosity with μ MT mice in which the endogenous heavy chain locus had been silenced by gene
10 targeting (Kitamura *et al.*, 1991, *supra*). Bone marrow (left three rows) and spleen cells (right three rows) from normal F1 mice, μ MT mice and 2 separately generated camel heavy chain mice bred to homozygosity with μ MT animals, camIgH(1) μ MT and camIgH(2) μ MT were stained with labelled antibodies against B220 (universal B-cell marker), c-kit (pro/pre B-cell marker), CD43 (pre B-cell marker), IgM (identifying surface
15 μ expression), CD21/35 (identifying mature B-cells that express antibodies) and Ig κ (identifying surface κ light chain expression). Analysis was carried out by flow cytometry as described (Zou *et al.*, 2003, J. Immunol. 170, 1354-1361).

The analysis shows (see Figure 9) that introduction of a camel heavy chain gene
20 reconstitutes B-cell development in the μ MT background. In bone marrow B220⁺ cells (14%) are present in camIgH(2) μ MT mice which suggests induced B-cell recovery by expression of the camel heavy chain gene. In the spleen the effect is more dramatic as 25% of mature B-cells, CD21/35⁺, are present in camIgH(2) μ MT mice. There is some recovery, 1.1%, in camIgH(1) μ MT mice and this low level is likely to be due to the site
25 of integration of the transgene, e.g. in a silencer region. As expected there is no recovery of mouse Ig expression.

The results show that expression of a camel heavy chain allows B-cell recovery in a heavy chain knockout (KO) mouse. This suggests that camel-type heavy chain antibody
30 repertoires can be expressed in the mouse background.

Example 5: Breeding with heavy (H) and light (L) chain knock-out (KO) mice

In this example, the feasibility of B-cell development in H chain only mice is tested. The experiments make use of our μ truncation mice (see Zou, X. *et al.*, 2001, *Int. Immunol.* 13: 1489-1499) which are bred with animals not expressing endogenous mouse L chain genes.

Mice carrying the rearranged camel heavy chain gene (see Example 3 above), were set up for breeding with mice in which the heavy chain locus and, separately, the kappa and lambda light chain locus had been silenced by gene targeting (see Kitamura, D. *et al.*, 1991, *supra*, and International patent application No: PCT/GB02/002867 published as WO03/000737). Homozygous animals were obtained.

Homozygous animals are analysed by flow cytometry to establish the state of B-cell development and IgH expression.

Example 6: Design of a human heavy chain locus that allows expression of camel-type single chain antibodies in mice

A human IgH YAC with V, D, J and C genes has been described (Nicholson *et al.*, 1999, *supra*; see Figure 10). The human IgH YAC is modified by truncation and removal of the C gene ($C\mu$ and $C\delta$ regions). For this a human C gamma (γ) gene (Flanagan and Rabbitts, 1982, *Nature* 300: 709-713; Brüggemann *et al.*, 1987, *J. Exp. Med.* 166: 1351-1361) without the CH1 exon, obtained by restriction digest or PCR, is subcloned into a YAC arm vector (Burke *et al.*, 1987, *Science* 236: 806-812). To allow homologous integration and C gene truncation, a region 5' of $C\mu$ ($C\mu$) is added to the human IgH YAC construct. This allows in yeast transfection the replacement of the region comprising the μ (μ) and delta (δ) C genes to form a IgH γ^A YAC construct (Figure 11). A loxP sequence can be added to permit future modification of the IgH γ^A YAC construct. Yeast methodologies are described in Guthrie and Fink, 1991, *Methods in Enzymology*, Vol 194, Academic Press). Suitable techniques for YAC modification are described in Popov *et al.*, 1996, *Gene* 177: 195-205 and in International patent application publication No:

WO00/26373.

Example 7: Introduction of a repertoire of unrearranged genes into mice

- 5 Protoplast fusion is used for YAC integration of the IgH γ^A YAC construct (see Example 6 and Figure 11) into ES cells. Chimeric mice are produced by blastocyst transfer and breeding established germline transmission. Further breeding with H and L KO mice allows analysis of B-cell development and expression of (diversified) single chain Ig from this modified IgH YAC.
- 10 For methods of YAC introduction and derivation of transgenic mice, see WO 93/05165; Davies, N.P. *et al.* (1996) Human antibody repertoires in transgenic mice: Manipulation and transfer of YACs. In: Antibody Engineering: A Practical Approach, J. McCafferty *et al.* (eds), IRL, Oxford, pp. 59-76; Hogan, B. *et al.* (1994a) Isolation, culture, and
- 15 manipulation of embryonic stem cells. In: Manipulating the mouse embryo, a laboratory manual, Cold Spring Laboratory Press, pp. 253-289; and Hogan, B. *et al.* (1994b). Production of transgenic mice. In Manipulating the mouse embryo, a laboratory manual, Cold Spring Laboratory Press, pp. 217-251.
- 20 If necessary expression of the IgH γ^A YAC can be enforced. For this transgenic mice carrying this YAC are bred with animals not expressing any immunoglobulin genes (see knockout mice in Example 4 above). This establishes a human heavy chain-only antibody repertoire and after immunisation specific single chain antibodies are obtainable.
- 25 It may also be desirable to introduce specific human single chain antibody gene configurations into mice or mice cells so that no rearrangement takes place and "monoclonal" antibodies are produced. *In situ* somatic mutation of these configurations may allow for some optimisation of binding to antigen.

Claims

1. A transgenic mouse capable of expressing a single chain antibody, in which expression includes either extracellular display or secretion or both.
5
2. The transgenic mouse according to claim 1, in which the single chain antibody is a heavy chain antibody.
3. The transgenic mouse according to claim 1, in which the single chain antibody
10 comprises a heavy chain domain linked to a light chain domain.
4. The transgenic mouse according to any of claims 1 to 3, in which the mouse carries immunoglobulin heavy and/or chain locus genes of a heterologous species for single chain antibody expression.
15
5. The transgenic mouse according to claim 4, in which the heterologous heavy and/or light chain locus genes include V_L and/or V_H , and/or D and/or J_H and/or C genes.
6. The transgenic mouse according to either of claim 4 or claim 5, in which a
20 heterologous heavy chain locus gene is modified (for example by mutation and/or deletion) to allow expression and/or antigen binding of the single chain antibody.
7. The transgenic mouse according to claim 6, in which a C region exon (for example, the C_H1 exon) of the heterologous heavy chain locus gene is modified.
25
8. The transgenic mouse according to either of claim 6 or claim 7, in which the V_H and/or complementary determining residues are modified.
9. The transgenic mouse according to any of claims 4 to 8, in which the heterologous
30 heavy and/or light chain locus genes are not rearranged and comprise a repertoire of V_H , D and J_H segments, or V_L and J_L segments, and a constant region gene.

10. The transgenic mouse according to claim 1, comprising a repertoire of genes encoding rearranged or germline variable V_H or V_L domains of a heterologous species, modified for single chain antibody expression and optionally antigen binding by modification of variable-region framework and/or CDR residues and/or constant-region
5 genes.
11. The transgenic mouse according to any preceding claim, in which any or all of the endogenous mouse heavy chain genes and/or light chain genes have been modified, functionally silenced and/or deleted.
10
12. The transgenic mouse according to any preceding claim, in which the single chain antibody is in monomeric or multimeric configuration.
13. The transgenic mouse according to any preceding claim, in which a repertoire of
15 single chain antibodies are expressed.
14. The transgenic mouse according to any of claims 4 to 13, in which the heterologous heavy and/or light chain locus genes or the repertoire of genes undergo rearrangement and expression in mouse B cells.
20
15. The transgenic mouse according to any of claims 4 to 14, in which the heterologous species is mammalian.
16. The transgenic mouse according to claim 15, in which the heterologous species is
25 noncamelid, for example human.
17. A method for the production of a transgenic mouse capable of expressing a single chain antibody having a heavy chain or a heavy chain linked to a light chain, comprising the steps of inserting immunoglobulin heavy or light chain locus genes of a heterologous
30 species into the mouse, allowing expression of the genes to form the single chain antibody which is expressed either by extracellular display or by secretion or both.

18. A single chain antibody produced by the transgenic mouse as defined in any of claims 1 to 16.
19. The single chain antibody of claim 18, in which the single chain antibody is in the
5 form of a monomer or multimers in which identical chains are associated.
20. The single chain antibody of claim 18, in which the antibody is in dimeric or multimeric form such that variable domains of the antibody bind antigen independently.
- 10 21. A monoclonal or polyclonal heavy chain only antibody, or a heavy-light chain chimeric antibody, which has a structure including a single domain antigen-combining V_H or V_L region and which is made upon immunisation of a mouse as defined in any of claims 1 to 16.
- 15 22. A method for producing the antibody of any of claims 18 to 21, comprising the step of immunising the mouse as defined in any of claims 1 to 16 with an antigen to elicit an immune response, the immune response comprising antigen-specific antibody production.
- 20 23. An antibody display library derived from the transgenic mouse as defined in any of claims 1 to 16, in which the display library comprises immunoglobulin heavy and/or light chain genes which are transcribed and translated *in vitro* to encode a population of single chain antibodies.
- 25 24. The display library of claim 23, wherein the library comprises lymphocyte DNA isolated from a mouse as defined in any of claims 1 to 16.
25. A method for the production of the display library as defined in either of claim 23 or claim 24, comprising the step of introducing the immunoglobulin heavy and/or light
30 chain genes into a bacterial, yeast, phage or ribosome display system.
26. An isolated non-camelid immunoglobulin locus comprising heavy chain genes

modified to encode a single chain antibody capable of being expressed *in vivo*.

27. The locus of claim 26, further comprising light chain genes.

5 28. The locus of claim 27, in which the heavy and light chain genes comprise variable genes which are modified at their V_H/V_L interface.

29. A hybridoma obtainable from a transgenic mouse according to any of claims 1 to 16 by fusion of a splenocyte from the transgenic mouse with a B-cell tumour line cell, and
10 subsequent selection of single clones.

30. A single chain antibody obtainable from a hybridoma according to claim 29.

31. The single chain antibody according to claim 30, in which the single chain
15 antibody is human.

32. A method for producing a repertoire of single chain antibodies in a mouse.

33. The method of claim 32, in which the mouse is as defined in any of claims 1 to 16.
20

34. A repertoire of single chain antibodies produced according to either of claim 32 or claim 33.






Fig. 1


2/10

**Fig. 2**

3/10

**Fig. 3**

4/10

**Fig. 4**

5/10




Fig. 5

6/10





Fig. 6

7/10

Fig. 7

8/10




Fig. 8

9/10




Fig. 9




Fig. 10




Fig. 11

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.